18.75USD-1.16%Mkt Cap: 1.18B USDP/E: —Last update: 2026-05-26
Zenas BioPharma, Inc., a clinical-stage biopharma company, engages in the development and commercialization of transformative immunology-based therapies. Its lead product candidate is obexelimab, a bifunctional monoclona…
Industry Peers
Biotechnology110.61BUSDP/E 25.8
106.49BDKKP/E 20.5
66.47BUSDP/E 15.5
46.51BEURP/E 30.5
43.17BEURP/E 35.9
39.41BUSDP/E 74.0
32.84BUSD—
31.18BSEKP/E 46.1
Indicators:|
Key Statistics
Company
Market Cap1.18B USD
Enterprise Value802.19M USD
Revenue (TTM)0 USD
Gross Profit-193.59M USD
Net Income (TTM)-377.74M USD
Revenue/Share0.0000 USD
Last Price18.75 USD
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees167
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-8.76
PEG—
EV/EBITDA-3.19
EV/Revenue—
P/SInfinity
P/B4.46
EPS (TTM)-9.10
EPS (Forward)-2.27
52W Range
8.91028% of range44.60
52W High44.60 USD
52W Low8.910 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin-3777.37%
ROE-156.00%
ROA-98.46%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-172.33M USD
CapEx (TTM)35.02M USD
FCF Margin—
FCF Yield-14.09%
Net Debt-450.38M USD
Net Debt/EBITDA1.79
Balance Sheet
Debt/Equity0.01
Current Ratio11.94
Quick Ratio11.74
Book Value/Sh4.444 USD
Cash/Share11.36 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.3 (Strong Buy)
Target (Mean)42.13 USD
Target Range22.00 USD – 55.00 USD
# Analysts8
Ownership
Shares Out.63.13M
Float39.68M
Insiders23.20%
Institutions94.30%
Short Interest
Short Ratio14.6d
Short % Float26.10%
Short % Out.17.40%
Shares Short10.85M
Short (prev mo.)9.36M
Technical
SMA 5020.52 (-8.6%)
SMA 20024.50 (-23.5%)
Beta—
S&P 52W Chg28.31%
Avg Vol (30d)513.79K
Avg Vol (10d)556.34K
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—